NNZ-2591 positive effects in Phelan-McDermid syndrome model
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Trofinetide ex-North America exclusive negotiation period
- Neuren and Lanstead agree to pause settlements for 120 days
- Neuren receives initial payment of US$10 million from ACADIA
- Neuren and ACADIA announce agreement for North America
- Announcement of buy-back - Appendix 3C
Later from Neuren Pharmaceuticals
- Preliminary Final Report and statutory accounts
- Neurens Rett syndrome Phase 2 trial published in Neurology
- Update on development plan for NNZ-2591
- NNZ-2591 positive effects in Angelman syndrome model
- NNZ-2591 positive effects in Pitt Hopkins syndrome model
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals